ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
    Huo, Xingfa
    Shen, Guoshuang
    Liu, Zhen
    Liang, Yuhua
    Li, Jinming
    Zhao, Fuxing
    Ren, Dengfeng
    Zhao, Jiuda
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 168
  • [32] Cardioprotective effect of crocin in patients with breast cancer receiving anthracycline-based chemotherapy: A randomized, double-blind, placebo-controlled study
    Li, Xinye
    Su, Xin
    Liang, Wanping
    Wang, Li
    Yuan, Chao
    Xu, Juping
    Zhang, Yijun
    Liu, Yan
    Ma, Ning
    Yang, Fan
    Yang, Yiyuan
    Tao, Liyuan
    Sun, Shipeng
    Shang, Hongcai
    Xing, Yanwei
    PHARMACOLOGICAL RESEARCH, 2025, 213
  • [33] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03) : E382 - E393
  • [34] Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
    Shimomura, Akihiko
    Yonemori, Kan
    Yoshida, Masayuki
    Yoshida, Teruhiko
    Yasojima, Hiroyuki
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Naito, Yoichi
    Shimizu, Satoru
    Nakamura, Rikiya
    Hamada, Akinobu
    Michimae, Hirofumi
    Hashimoto, Jun
    Yamamoto, Harukaze
    Kawachi, Asuka
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    TRANSLATIONAL ONCOLOGY, 2019, 12 (10): : 1386 - 1394
  • [35] Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
    Romero, Iris L.
    Lengyel, Ernst
    Hendrickson, Andrea E. Wahner
    Rodriguez, Gustavo C.
    Leath, Charles A.
    Rocconi, Rodney P.
    Goodheart, Michael J.
    Dewdne, Summer
    Karrison, Theodore
    Fleming, Gini F.
    Yamada, Diane
    GYNECOLOGIC ONCOLOGY, 2025, 194 : 18 - 24
  • [36] A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
    Ho, Alice Y.
    Barker, Christopher A.
    Arnold, Brittany B.
    Powell, Simon N.
    Hu, Zishuo I.
    Gucalp, Ayca
    Lebron-Zapata, Lizza
    Wen, Hannah Y.
    Kallman, Cindy
    D'Agnolo, Alessandro
    Zhang, Zhigang
    Flynn, Jessica
    Dunn, Samantha A.
    McArthur, Heather L.
    CANCER, 2020, 126 (04) : 850 - 860
  • [37] Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
    Recchia, Francesco
    Candeloro, Giampiero
    Desideri, Giovambattista
    Necozione, Stefano
    Recchia, Cornelia O. C.
    Cirulli, Vincenzo
    Rea, Silvio
    CANCER MEDICINE, 2012, 1 (01): : 89 - 95
  • [38] Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
    Huang, Chiun-Sheng
    Yu, Alice L.
    Tseng, Ling-Ming
    Chow, Louis W. C.
    Hou, Ming-Feng
    Hurvitz, Sara A.
    Schwab, Richard B.
    Murray, James L.
    Chang, Hsien-Kun
    Chang, Hong-Tai
    Chen, Shin-Cheh
    Kim, Sung-Bae
    Hung, Jung-Tung
    Ueng, Shir-Hwa
    Lee, Su-Hua
    Chen, Chwen-Cheng
    Rugo, Hope S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [39] Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
    Bell, R.
    Brown, J.
    Parmar, M.
    Toi, M.
    Suter, T.
    Steger, G. G.
    Pivot, X.
    Mackey, J.
    Jackisch, C.
    Dent, R.
    Hall, P.
    Xu, N.
    Morales, L.
    Provencher, L.
    Hegg, R.
    Vanlemmens, L.
    Kirsch, A.
    Schneeweiss, A.
    Masuda, N.
    Overkamp, F.
    Cameron, D.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 754 - 760
  • [40] IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
    Hack, Stephen P.
    Verret, Wendy
    Mulla, Sohail
    Liu, Bo
    Wang, Yulei
    Macarulla, Teresa
    Ren, Zhenggang
    El-Khoueiry, Anthony B.
    Zhu, Andrew X.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345